Physician profile
Chathula Pasindu Kumarasinghe
NPI 1174184840
$2,669.21
in general payments reported to CMS, 2019-2025
12 companies · $513 in 2025
The $513 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $35.67 · 2022: $398 · 2023: $1,021 · 2024: $702 · 2025: $513.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,802 · Education: $434.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,801.56 |
| Education | $433.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $1,074.88 | 2021-2024 | Padcev, Adcetris, Tukysa |
| Bayer Healthcare Pharmaceuticals INC. | $490.08 | 2023-2025 | |
| Abbvie INC. | $349.99 | 2023-2024 | |
| Pfizer INC. | $280.06 | 2022-2025 | |
| Blueprint Medicines Corporation | $125.00 | 2024 | Ayvakit |
| Mirati Therapeutics, INC. | $125.00 | 2023 | Krazati |
| Intera Oncology, INC | $92.03 | 2025 | Intera |
| G1 Therapeutics, INC. | $39.57 | 2022 | |
| Sobi, INC | $28.05 | 2025 | |
| Eisai INC. | $25.24 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $24.99 | 2025 | Enhertu |
| Janssen Biotech, INC. | $14.32 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chathula Kumarasinghe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.